TerminatedPhase 4

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

Stopped: termination by sponsor

United States15 participantsStarted 2017-01-10

Plain-language summary

This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Aspartate aminotransferase (AST) \>3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \>3x ULN
✕. Total bilirubin \>2.0 mg/dL (34.2 µmol/L)
✕. Positive serologic evidence of current infectious liver disease including Hepatitis B viral antibody IGM, Hepatitis B surface antigen and Hepatitis C virus antibody
✕. Liver function tests more than 3 times the upper limit of normal

What they're measuring

Change From Baseline in Urinary Albuminuria Levels

Timeframe: baseline and 52 weeks

Trial details

NCT IDNCT03029351

SponsorUniversity at Buffalo

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-07

Results submitted2023-12-30

View on ClinicalTrials.gov More Type2 Diabetes trials